{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'Review all Inclusion and Exclusion Criteria.', 'Record medical/surgical history and from subjects not previously enrolled in SPIMM-', '300, including previous genetic testing results (as described in Section 6.3.1). NOTE:', 'genetic testing will not be provided as part of the SPIMM-301 trial.', 'Record concomitant medication (including supplements and vitamins) (as described', 'in Section 6.3.1).', 'During the screening period, assess for any pre-treatment event and record as medical', 'history or AE (as described in Sections 9.3).', 'Complete a physical examination (as described in Section 6.3.2).', 'Collect vital signs (as described in Section 6.3.4).', 'Complete 12-lead resting ECG (as described in Section 6.3.5).', 'Complete the Columbia Suicide Severity Rating Scale (C-SSRS)', '\"Baseline/Screening\" (as described in Section 6.3.3 and provided in Appendix 5).', 'Draw blood and collect urine for clinical laboratory testing and urinalysis as outlined', 'in Appendix 4 (and as described in Section 6.3.6).', 'Complete serum pregnancy test (only for women of childbearing potential).', 'Provide subject with the electronic or paper diary and train subject on the procedure', 'to complete the PMMSA. Complete the PMMSA (as described in Section 6.3.8 and', 'as outlined in Appendix 8) and collect results in the electronic or paper diary. The', 'PMMSA should be completed daily during the Screening Period.', 'Complete the Neuro-QoL Fatigue (as described in Section 6.3.9 and as provided in', 'Appendix 9).', 'Complete the EQ-5D-5L (as described in Section 6.3.10 and as provided in', 'Appendix 10).', 'Complete the Patient Global Impression (PGI) Scales (as described in Section 6.3.11', 'and as provided in Appendix 11).', 'Complete the Clinician Global Impression (CGI) Scales (as described in', 'Section 6.3.12 and as provided in Appendix 12).', 'Conduct the 6MWT (as described in Section 6.3.13 and as outlined in Appendix 13).', '6.2.1.2.', 'Baseline Visit (Day 1)', 'NOTE: Subjects who have been deemed eligible during Screening Period will return for', 'randomization and the following procedures will be performed. The 6MWT must be completed', 'after all other trial assessments. On days of trial visits, the IMP should be administered at the', 'clinic. At Baseline Visit, the IMP administration will occur after the completion of all Visit', 'procedures.', 'Review all Inclusion Criteria and Exclusion Criteria.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '42']['SPIMM-301 Version 4.0', '15 June 2018', 'Assess AEs/ADEs related to a trial procedure and/or meet seriousness criteria that', 'occurred since the signing of the informed consent form as Section 9.9.2.', 'Update medical/surgical history during the Screening Period (as described in', 'Section 6.3.1).', 'Update concomitant medication/procedures (including supplements and vitamins)', 'during the Screening Period (as described in Section 6.3.1).', 'Complete a physical examination (as described in Section 6.3.2).', 'Collect vital signs (as described in Section 6.3.4).', 'Complete 12-lead resting ECG (as described in Section 6.3.5).', 'Complete the C-SSRS \"Since Last Visit\" (as described in Section 6.3.3 and provided', 'in Appendix 6).', 'Draw blood and collect urine for clinical laboratory testing and urinalysis as outlined', 'in Appendix 4 (and as described in Section 6.3.6). An additional blood sample will be', 'collected and stored for assessing the immunogenicity potential of the IMP.', 'Complete urine pregnancy test (only for women of childbearing potential).', 'Complete the PMMSA (as described in Section 6.3.8 and as outlined in Appendix 8)', 'and collect results in the electronic or paper diary. The PMMSA should be completed', 'daily during the Treatment Period.', 'Complete the Neuro-QoL Fatigue (as described in Section 6.3.9 and as provided in', 'Appendix 9).', 'Complete the EQ-5D-5L (as described in Section 6.3.10 and as provided in', 'Appendix 10).', 'Complete the Patient Global Impression (PGI) Scales (as described in Section 6.3.11', 'and as provided in Appendix 11).', 'Complete the Clinician Global Impression (CGI) Scales (as described in', 'Section 6.3.12 and as provided in Appendix 12).', 'Conduct the 6MWT (as described in Section 6.3.13 and as outlined in Appendix 13).', 'If the subject meets all SPIMM-301 eligibility criteria and has completed all baseline', 'assessments, the subject may be randomized (as described in Section 8.5). Following', 'randomization:', 'Provide elamipretide delivery system supplies.', 'Train subject (and caregivers if needed) on the procedure for administration of the', 'elamipretide delivery system, and recording of the location (injection in the abdomen,', 'rotating around the four abdominal quadrants, or other appropriate location [after', 'Investigator consultation with the Sponsor]) and time (at approximately the same time', 'each day [e.g., early morning, noon, or early afternoon]) of the IMP administration in', 'the electronic or paper diary.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '43']\n\n###\n\n", "completion": "END"}